Overexpression of cyclooxygenase-2 predisposes to podocyte injury.
Increased podocyte cyclooxygenase-2 (COX-2) expression is seen in rats after renal ablation and Thy-1 nephritis and in cultured murine podocytes in response to mechanical stress. For investigation of whether COX-2 overexpression plays a role in podocyte injury, transgenic B6/D2 mice in which COX-2 expression was driven by a nephrin promoter were established. Selective upregulation of COX-2 expression in podocytes of transgenic mouse kidneys was confirmed by immunoblotting and immunohistochemistry. Whether upregulation of podocyte-specific COX-2 expression enhanced sensitivity to the development of Adriamycin nephropathy was examined. Adriamycin administration induced dramatically more albuminuria and foot process effacement and reduced glomerular nephrin mRNA and immunoreactivity in transgenic mice compared with wild-type littermates. Adriamycin also markedly increased immunoreactive COX-2 expression in podocytes from transgenic mice compared with the wild-type mice. Reverse transcriptase-PCR indicated that this increase represented a stimulation of endogenous COX-2 mRNA expression rather than COX-2 mRNA driven by the nephrin promoter. Balb/C mice, which are susceptible to renal injury by Adriamycin, also increased podocyte COX-2 expression and reduced nephrin expression in response to administration of the drug. Long-term treatment with the COX-2-specific inhibitor SC58236 ameliorated the albuminuria that was induced by Adriamycin in the transgenic mice. SC58236 also reduced Adriamycin-induced foot process effacement in both the COX-2 transgenic mice and Balb/C mice. Therefore, overexpression of COX-2 may predispose podocytes to further injury.
Cheng
Huifang
H
Division of Nephrology, C3115 MCN, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. huifang.cheng@vanderbilt.edu
Wang
Suwan
S
Jo
Young-Il
YI
Hao
Chuan-Ming
CM
Zhang
Mingzhi
M
Fan
Xiaofeng
X
Kennedy
Chris
C
Breyer
Matthew D
MD
Moeckel
Gilbert W
GW
Harris
Raymond C
RC
D000818:Animals; D051546:Cyclooxygenase 2 / Q000235:genetics* / Q000378:metabolism; D004317:Doxorubicin / Q000633:toxicity; D015971:Gene Expression Regulation, Enzymologic; D007668:Kidney / Q000473:pathology; D007678:Kidney Glomerulus / Q000201:enzymology / Q000473:pathology; D008565:Membrane Proteins / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D050199:Podocytes / Q000201:enzymology* / Q000473:pathology*; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic
D008565:Membrane Proteins; C113267:nephrin; D004317:Doxorubicin; D051546:Cyclooxygenase 2